677 related articles for article (PubMed ID: 28159736)
1. Myeloproliferative neoplasm stem cells.
Mead AJ; Mullally A
Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
[TBL] [Abstract][Full Text] [Related]
2. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
Edahiro Y; Araki M; Komatsu N
Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
[TBL] [Abstract][Full Text] [Related]
3. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
4. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
[TBL] [Abstract][Full Text] [Related]
5. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
6. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.
Jia R; Kralovics R
Int J Hematol; 2020 Feb; 111(2):182-191. PubMed ID: 31741139
[TBL] [Abstract][Full Text] [Related]
7. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice.
Shide K; Kameda T; Kamiunten A; Ozono Y; Tahira Y; Yokomizo-Nakano T; Kubota S; Ono M; Ikeda K; Sekine M; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Iwakiri H; Hasuike S; Nagata K; Sashida G; Shimoda K
Blood; 2020 Jul; 136(1):106-118. PubMed ID: 32219445
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
9. Genetic-pathologic characterization of myeloproliferative neoplasms.
Kim Y; Park J; Jo I; Lee GD; Kim J; Kwon A; Choi H; Jang W; Chae H; Han K; Eom KS; Cho BS; Lee SE; Yang J; Shin SH; Kim H; Ko YH; Park H; Jin JY; Lee S; Jekarl DW; Yahng SA; Kim M
Exp Mol Med; 2016 Jul; 48(7):e247. PubMed ID: 27444979
[TBL] [Abstract][Full Text] [Related]
10. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Rampal R; Levine RL
Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
[TBL] [Abstract][Full Text] [Related]
11. Targets in MPNs and potential therapeutics.
Levy G; Mambet C; Pecquet C; Bailly S; Havelange V; Diaconu CC; Constantinescu SN
Int Rev Cell Mol Biol; 2022; 366():41-81. PubMed ID: 35153006
[TBL] [Abstract][Full Text] [Related]
12. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
13. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.
Arranz L; Sánchez-Aguilera A; Martín-Pérez D; Isern J; Langa X; Tzankov A; Lundberg P; Muntión S; Tzeng YS; Lai DM; Schwaller J; Skoda RC; Méndez-Ferrer S
Nature; 2014 Aug; 512(7512):78-81. PubMed ID: 25043017
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
[TBL] [Abstract][Full Text] [Related]
16. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
[TBL] [Abstract][Full Text] [Related]
17. pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms.
Sakr H; Clark Schneider K; Murugesan G; Bodo J; Hsi ED; Cook JR
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):147-152. PubMed ID: 27258562
[TBL] [Abstract][Full Text] [Related]
18. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
Sangkhae V; Etheridge SL; Kaushansky K; Hitchcock IS
Blood; 2014 Dec; 124(26):3956-63. PubMed ID: 25339357
[TBL] [Abstract][Full Text] [Related]
19. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.
Mosca M; Hermange G; Tisserand A; Noble R; Marzac C; Marty C; Le Sueur C; Campario H; Vertenoeil G; El-Khoury M; Catelain C; Rameau P; Gella C; Lenglet J; Casadevall N; Favier R; Solary E; Cassinat B; Kiladjian JJ; Constantinescu SN; Pasquier F; Hochberg ME; Raslova H; Villeval JL; Girodon F; Vainchenker W; Cournède PH; Plo I
Blood; 2021 Dec; 138(22):2231-2243. PubMed ID: 34407546
[TBL] [Abstract][Full Text] [Related]
20. [Gene mutations in myeloproliferative neoplasms].
Araki M; Morishita S; Komatsu N
Rinsho Ketsueki; 2016; 57(12):2526-2534. PubMed ID: 28090022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
